Harrow Inc - Company Profile
Powered by 
All the sales intelligence you need on Harrow Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Harrow Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Harrow Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Business Description
Harrow Inc (Harrow) is primarily engaged in the discovery, development, and commercialization of innovative ophthalmic pharmaceutical products for the US. market. The company owns commercial rights to one of the largest portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It also owns and operates ImprimisRx, one of the nation’s leading ophthalmology-focused pharmaceutical-compounding businesses. Additionally, Harrow holds a noncontrolling equity interest in Melt Pharmaceuticals, Inc. and two other companies.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
R&D Overview
Harrow's R&D initiatives focus on developing and commercializing differentiated pharmaceutical therapies designed to address unmet needs in eye care and selected adjacent markets. The development pipeline is weighted toward late-stage and near-commercial assets with demonstrated clinical utility and clearer regulatory pathways. Current development-stage programs include MELT-300, H-N08, CR-01, and MELT-210, with potential launches ranging from 2028 to 2029. The company employs a disciplined, capital-efficient development strategy to advance these programs. The R&D unit of the company is responsible for performing research and development activities, including managing expenses related to salaries, benefits, overhead, clinical trials, contract services, and outsourced contracts. The unit plays a crucial role in advancing the company's development pipeline and ensuring the successful execution of clinical and non-clinical trials. In FY2025, the company incurred R&D expenses of US$20.9 million
Business Segments
Overview
Includes activities of the Company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain of our branded products.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Overview
Includes activities in the Company’s ophthalmology-focused pharmaceutical compounding business.
Performance
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer